Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...

If Oz is confirmed by the U.S. Senate, he'll immediately lead an agency that provides health care for 160 million Americans ...

We recently published a list of 12 Best Safe Dividend Stocks for 2025. In this article, we are going to take a look at where ...

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...

The health-care sector has been rebounding recently following a sharp selloff in recent weeks amid hopes that controversy would die down. The health-care industry group was among the leading S&P 500 ...

The Federal Trade Commission said in its second interim staff report on prescription-drug middlemen that the "significant markups" in prices above what the drugs cost generated an extra $7.3 billion ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.